Westerkirk Capital’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.67M Buy
28,729
+25,996
+951% +$5.01M 0.61% 41
2025
Q4
$502K Sell
2,733
-3,172
-54% -$556K 0.05% 153
2025
Q3
$906K Buy
+5,905
New +$894K 0.1% 151

Other funds holding AZN

Westerkirk Capital's AZN Position: Q1 2026 in Review

Westerkirk Capital increased its AstraZeneca (AZN) stake by 951% in Q1 2026, buying an estimated $5.01M and bringing the position to 28,729 shares worth $5.67M. The position accounts for 0.61% of the portfolio, ranked #41.

Westerkirk Capital first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Westerkirk Capital held 28,729 shares of AstraZeneca worth $5.67M as of Q1 2026.
  • Westerkirk Capital bought 25,996 AstraZeneca shares in Q1 2026, an estimated $5.01M.
  • AstraZeneca made up 0.61% of Westerkirk Capital's portfolio in Q1 2026, its #41 holding.
  • Westerkirk Capital first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Westerkirk Capital's 13F filing for Q1 2026, filed 14 May 2026.